A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

Cliniques Universitaires Saint Luc, Brussels

Centre Hospitalier Universitaire Sart Tilman Liege, Brussels

Mt. Sinai Medical Center, New York

Memorial Sloan-Kettering Cancer Center, New York

Weill Cornell Medical College/NY Presbyterial Hospital, New York

Montefiore Medical Center, The Bronx

Allegheny-Singer Research Institute, Pittsburgh

Western Pennsylvania Hospital, Pittsburgh

Thomas Jefferson University, Philadelphia

Johns Hopkins University, Baltimore

Wake Forest, Winston-Salem

Duke Cancer Institute, Durham

Levine Cancer Institute/Carolinas Health, Charlotte

Hollings Cancer Center, Charleston

Winship Cancer Institute-Emory, Atlanta

Northside Hospital, Atlanta

University of Miami Hospital, Miami

Vanderbilt University Medical Center, Nashville

The Universit of Iowa, Iowa City

Cincinnati Children's Hospital, Cincinnati

The Jewish Hospital, Cincinnati

University of Michigan, Ann Arbor

Harper University Hospital, Detroit

Henry Ford Hospital, Detroit

University of Minnesota, Minneapolis

Northwestern Memorial Hospital, Chicago

University of Chicago, Chicago

Baylor University Medical Center, Dallas

University of Texas Southwestern Medical Center at Dallas, Dallas

MD Anderson Cancer Center, Houston

Methodist Healthcare of San Antonio, San Antonio

University of Colorado, Denver

Colorado Blood Cancer Institute, Denver

University of Utah, Huntsman Cancer Institute, Salt Lake City

Intermountain Healthcare, Salt Lake City

UCLA Medical Center, Los Angeles

University of California, San Diego-Moores Cancer Center, La Jolla

Fred Hutchinson Cancer Research Center, Seattle

Beth Isreal Decaconess Medical Center, Boston

Brigham and Womens Hospital, Boston

Hackensack University, Hackensack

University of Toronto, Toronto

Centre Hospitalier Universitaire de Montreal, Hopital Maisonneuve-Rosemont, Montreal